Affinity-matured B cell responses neutralizing type-I interferons underlie severe viral infections.
Fournier M, Vanderkerken M, Dorgham K, Bastard P, Ahouzi O, Duquerroy S, Nguyen NK, Broutin M, Charlet M, Vandenberghe A, Van Endert P, Bizien L, Da Mata-Jardin O, Ferriño-Iriarte A, Haouz A, Belmondo T, Hüe S, Borghesi A, Rodríguez-Gallego C, Vinh DC, Andreakos E, Haerynck F, Halwani R, Pan-Hammarström Q, Björkström NK, Strunz B, Mogensen TH; COVID Human Genetic Effort; Piralla A, Varchetta S, Freixinet J, Roussel L, Trouillet Assant S, Neven B, Levy R, le Voyer T, Delmonte OM, O'Farrelly C, Rivière J, Amador Borrero B, Servettaz A, Kouyos RD, Kaufmann DE, Crickx E, Michel M, Puel A, Abel L, Luyt CE, Mathian A, Kisand K, Duffy D, Quintana-Murci L, Amoura Z, Hale BG, Weill JC, Casanova JL, Rey FA, Gorochov G, Chappert P, Mahévas M.
Fournier M, et al. Among authors: michel m.
Cell. 2026 May 6:S0092-8674(26)00438-1. doi: 10.1016/j.cell.2026.04.013. Online ahead of print.
Cell. 2026.
PMID: 42097138